{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071153","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.123314+00:00","generated_at":"2026-06-21T23:26:42.538637+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jasper Therapeutics Q3 net loss $11.9M; cash $51M; positive JSP191 data in Fanconi Anemia","bullets":["Net loss of $11.9M for Q3 2022 vs $3.4M in Q3 2021; R&D expenses $9.0M, G&A $3.7M.","Cash and equivalents $51.0M as of Sept 30, 2022, expected to fund operations through early 2023.","Positive clinical data: JSP191 conditioning achieved 100% donor chimerism in first two Fanconi Anemia patients.","FDA Fast Track designation granted for JSP191 in Severe Combined Immunodeficiency (SCID) transplant.","Registrational study in AML/MDS and new MDS second-line study expected to start Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071153","json":"https://secwatch.observer/filing/0001213900-22-071153.json","markdown":"https://secwatch.observer/filing/0001213900-22-071153.md","text":"https://secwatch.observer/filing/0001213900-22-071153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/0001213900-22-071153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/ea168345-8k_jasperthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:26:42.538637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b7ef24b5b0bb168cccd7e5618c2b76daab58638","claim":"Jasper Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $11.9 million.","evidence_excerpt":"Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390022071153/0001213900-22-071153-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$11.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}